baber/WOPTO huggingface dataset:
Patent NZ-212085-A (NZ)
Title: A tendamistat signal peptide used for the production of recombinant gene products excluding tendamistat that can be excreted from streptomyces
Inventor: KOLLER K-P
IPC: C12P19/34
Filed: 1985-05-15
Abstract: 1. Claims for the contracting states : BE. CH. LI. DE. FR. GB. IT. LU. NL. SE DNA sequence B, obtainable from Streptomyces tendae strains, which produce tendamistat and have preferably been treated with sublethal doses of acriflavine, by isolation of the complete DNA, digestion with Pst l, Southern hybridization with the DNA sequence A, 5'-(**32 P-)CCT TCA GTG TCG TCT TCG TA-3' (A) isolation of the 2.3 kb Pst l fragment, cutting with BamHl, Southern hybridization with the sequence A, isolation of the 0.94 kb Pst l-BamHl subfragment, cutting with Sau 3a, Southern hybridization with the sequence A, isolation of the 0.525 kb BamHi-Sau 3a subfragment and sequencing of the DNA, and which has the following features : a) it is located immediately upstream of the tendamistat structural gene, b) it codes at the amino terminal end for Met-Arg-Val-Arg-Ala-Leu-Arg, c) it codes at the carboxyl terminal end for Ala-Ser-Ala and d) it codes in the middle for a hydrophobic region X which comprises 10 to 25, preferably 17 to 20, amino acids. 1. Claims for contracting state AT A process for the preparation of polypeptides composed of genetically codable amino acids, characterized by the expression, in a host cell of the genus Streptomyces, of a gene structure which contains in the reading frame with the structural gene for the desired polypeptide the DNA sequence B of a prepeptide, which sequence is obtainable from Streptomyces tendae strains, which produce tendamistat and have preferably been treated with sublethal doses of acriflavine, by isolation of the complete DNA, digestion with Pst l, Southern hybridization with the DNA sequence A, 5'-(**32 P-)CCT TCA GTG TCG TCT TCG TA-3' (A) isolation of the 2.3 kb Pst l fragment, cutting with BamHI, Southern hybridization with the sequence A, isolation of the 0.94 kb Pst l-BamHl subfragment, cutting with Sau 3a, Southern hybriridization with the sequence A, isolation of the 0.525 kb BamHl-Sau 3a subfragment and sequencing of the DNA, and a) is located immediately upstream of the structural gene, b) codes at the amino terminal end for Met-Arg-Val-Arg-Ala-Leu-Arg, c) codes at the carboxyl terminal end for Ala-Ser-Ala and d) codes in the middle for a hydrophobic region X which comprises 10 to 25 amino acids.
Patent NZ-218028-A (NZ)
Title: Benzimidazole derivatives and pharmaceutical compositions
Inventor: ALMINGER T B
IPC: C07D491/113
Filed: 1986-10-22
Abstract: Novel compounds of the formula <CHEM> pharmaceutical compositions containing such compounds as active ingredient, and the use of the compounds in medicine.
Patent NZ-223847-A (NZ)
Title: Substituted piperazine derivatives and pharmaceutical compositions
Inventor: VAN DAELE G H P
IPC: A61P25/20
Filed: 1988-03-10
Abstract: A chemical compound having the formula <CHEM> the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof,   R<1> and R<2>   each independently are hydrogen or C1-6alkyl; X   is C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, aminocarbonyl, mono- and di(C1-6alkyl)aminocarbonyl, carboxyl, C1-6alkyloxycarbonyl, (aminocarbonyl)C1-6alkyl, Ämono- and di(C1-6alkyl)aminocarbonylÜC1-6alkyl, carboxylC1-6alkyl, (C1-6alkyloxycarbonyl)C1-6alkyl or (hydroxyC1-6alkyl)aminocarboxyl; m   is 1 or 2; n is 1 to 4; Ar   is optionally substituted phenyl; optionally substituted pyridinyl; optionally substituted pyrazolyl; or a radical of formula <CHEM> Q' is arylethyl, arylethenyl, aryloxymethyl, diarylmethoxy, 2,2-diarylethenyl, diarylmethylcarbonyl, arylcarbonylmethyl, mono- and diarylaminocarbonyl, diarylethyl or arylaminomethyl.   Process for preparing said compounds and pharmaceutical compositions comprising them are also disclosed.
Patent NZ-226129-A (NZ)
Title: Monoclonal anti-idiotypic antibodies wherein the idiotype is directed by tumour antigens; their production and use
Inventor: HELLSTROM INGEGERD
IPC: C12N15/00
Filed: 1988-09-12
Abstract: The present invention relates to methods which utilize anti-idiotypic antibodies, or fragments thereof, for tumor immunotherapy or immunoprophylaxis. Monoclonal anti-idiotypic antibodies which recognize an idiotype present on a second antibody or on a T lymphocyte or on an immune suppressor factor which is directed against a defined tumor antigen, can be used for immunization against a tumor, for immune anti-tumor activation or inhibition of suppression, or for in vitro activation of lymphocytes to be used in adoptive immunotherapy. The anti-idiotypic antibodies, or fragments thereof, can also be used to monitor anti-antibody induction in patients undergoing passive immunization to a tumor antigen by administration of anti-tumor antibody. In another embodiment, administration of T lymphocytes which express an idiotype directed against a defined tumor antigen can be used to transfer delayed-type hypersensitivity to the tumor. In another method of the invention, the induction of anti-idiotypic antibodies in vivo by administration of anti-tumor antibody or immune cells or factors exhibiting an anti-tumor idiotype can be therapeutically valuable.
Patent NZ-240996-A (NZ)
Title: Beverage dispenser; beverage flows when handle pivotted in one direction
Inventor: SMITH TREVOR GEORGE
IPC: B67D1/14
Filed: 1991-12-16
Abstract: A beer engine is provided that simulates a traditional beer engine/hand-pull, i.e. beer or the like is only dispensed while an operating handle is being pulled. Pivotal movement of the handle (6) towards a user about a pivot axis (8) causes translational movement of the pivot axis in order to operate a valve (3) to permit beer or the like to be dispensed. Upon this pivotal movement of the handle (6) being stopped or reversed, spring means (5, 10) urge the pivot axis in the opposite direction to allow the valve to close automatically.
Patent NZ-245224-A (NZ)
Title: Removal of halide impurities from liquids or vapours
Inventor: SCATES MARK O
IPC: C07C53/08
Filed: 1992-11-23
Abstract: A method is provided for removing iodide compounds, particularly alkyl iodide compounds, from iodine-containing liquids, particularly carboxylic acids and anhydrides manufactured by the carbonylation of alcohols, ethers, esters, and the like in the presence of a rhodium catalyst and an alkali metal or alkaline earth metal salt, particularly a lithium salt, wherein the carboxylic acid or anhydride is contacted with a silver or mercury salt coordinated to a polymeric resin containing functional groups having the capability to quaternize with or form ionic salts with the alkyl halides.
Patent NZ-269602-A (NZ)
Title: Dendritic macromolecules prepared by addition of an ethylenically unsaturated cyanide to a core molecule, followed by reduction of the nitrile groups to amine groups and subsequent further additions and reductions
Inventor: DE BRABANDER-VAN DEN BERG ELLE
IPC: C09D201/00
Filed: 1994-07-04
Abstract: The invention relates to a process for the preparation of a dendritic macromolecule, wherein an amount of a core molecule comprising at least one functional group is dissolved in a solvent, after which alternatingly an addition reaction and a hydrogenation reaction are carried out, during the addition reaction vinyl cyanide units being added to the solution which react with the functional groups in such a manner that a dendritic macromolecule with terminal cyanide groups is formed, and during the hydrogenation reaction the cyanide groups being reduced in solution by means of hydrogen and a suitable catalyst in such a manner that functional amine groups are formed, wherein the solvent in which the hydrogenation reaction takes place is an alcohol which contains an amount of ammonia, the molar ratio between the amount of ammonia and the number of cyanide groups being higher than 0.8.
Patent NZ-271238-A (NZ)
Title: Peptide derivatives with one of three classes of substitutent group attached
Inventor: KIM SUN HYUK
IPC: A61P5/02
Filed: 1994-08-08
Abstract: Peptide derivatives containing one or more substituents separately linked by an amide, amino or sulfonamide bond to an amino group on either the N-terminal end or side chain of a biologically active peptide moiety. The peptide derivatives have relatively enhanced biological activity when compared to the corresponding peptide alone.
Patent NZ-276575-A (NZ)
Title: Locating and identifying a digital control channel in a radiocommunication system
Inventor: HENRY RAY
IPC: H04L12/56
Filed: 1994-11-01
Abstract: A method for obtaining a report from a mobile station on the status of frames comprising an entire message transmitted to the mobile station is disclosed. First, a polling request is sent to the mobile station from a base station. A status report is then sent to the base station. The polling request specifies whether the mobile station should send the status report on a reservation basis (using a reserved frame) or on a contention basis (using an idle frame). The mobile station then transmits a bit map to the communication system to indicate which frames have been correctly received by the mobile station at the point when it received the polling request.
Patent NZ-311410-A (NZ)
Title: 2-(naphthyl or phenyl) substituted phenyl sulphonylamino derivatives useful as factor Xa inhibitors
Inventor: ILLIG CARL R
IPC: A61K31/44
Filed: 1996-06-07
Abstract: The phenyl sulphonylamino derivatives or a pharmaceutically acceptable salt thereof has the formula (I) wherein: R1 is an optionally substituted aryl; R2 is H, alkyl, cycloalkyl or aryl; R3 is H, OH or alkoxy; R4 is NH, quinuclidinyl, piperidinyl, optionally substituted pyridyl or substituted phenyl; X is -CH2- or -CO- and X is attached to the benzene ring in the ortho, meta or para position to the sulphonylamino; n is 0 to 8; provided that (i) when R1 is phenyl and R4 is phenyl substituted with two substituents, the substituents are not both OH or both alkoxy and (ii) when R2 is H or CH3, R3 is H, R4 is unsubstituted pyridyl and n is 0 or 1 then R1 is other than unsubstituted phenyl. A pharmaceutical composition thereof is useful for treating stroke, thrombosis, ischemia, restenosis or inflammation.
Patent NZ-321695-A (NZ)
Title: Means and method for the preparation of sealings in oil and gas wells
Inventor: DAHL-JORGENSEN EINAR
IPC: C09K8/508
Filed: 1996-10-25
Abstract: Agent and method for establishing different types of zone sealings particularly in oil wells and gas wells, wherein the zone to be sealed is supplied with a composition comprising: monomers, an initiator for heat-induced production of free radicals, a pot life extending inhibitor for stabilization of free radicals, and optionally other additives. The composition is subjected to radical polymerization induced by heat in the well zone and at a temperature of 5-120  DEG C, and establishes a cured mass, particularly at temperatures in the range of 65-100  DEG C. The composition is supplied with an at least partly unsaturated prepolymer selected from the group consisting of polyester and epoxy vinylester, including one or more vinyl-containing co-monomers selected from the group consisting of styrene, vinyltoluene, 2-hydroxyethyl-methacrylate and 2-hydroxypropyl-methacrylate. The prepolymer is present in a quantity of 15-75 weight parts and the vinyl-containing co-monomers are added in a quantity of 75-15 weight parts. The composition is particularly suited for low temperature applications.
Patent NZ-322489-A (NZ)
Title: Protectedly performing a transaction, using electronic payment means and a payment station, includes repeated execution of an interrogation step
Inventor: WISSENBURGH JELLE
IPC: G07F7/08
Filed: 1996-11-14
Abstract: The invention relates to a method for protected transactions involving a so-called smart card and a terminal, such as a cash register. In order to prevent the smart card from simultaneously carrying out transactions with several terminals, the invention provides an authentication value which is used in the data exchange between the smart card and the terminal to uniquely identify subsequent steps of the transaction.
Patent NZ-331467-A (NZ)
Title: Method for fluidizing tars by contacting tar with a surfactant followed by an inorganic acid and a carrier
Inventor: HILL DEAN PHILIP
IPC: C09K23/12
Filed: 1997-02-20
Abstract: rocess for the preparation of an aqueous tar suspoemulsion by mixing a mixture comprising: (a)	a viscous tar composition formed from a tar, from inorganic solids and, optionally, from water; (b)	water (W); (c)	a surface-active agent (SA) exhibiting an HLB of at least 10 and, optionally, (d)	a thickening water-soluble polymer (TWP) with a molecular mass of greater than 10,000, the relative amounts of constituents (W), (SA) and, optionally, (TWP) being such that the viscosity of the (W) + (SA) + optional (TWP) mixture is preferably equal to or greater than the viscosity of the said tar, and then optional dilution of the mixture obtained with water or with an aqueous acidic solution. The present invention further relates to a method for fluidizing acidic tars/sludges comprising contacting the tar/sludge with sulphuric acid and a surfactant. Optionally, a carrier for the surfactant's incorporation into the tar/sludge can be utilized. This provides an effective process for cleaning sulphuric acid tars/sludges from containers/vessels such as transportation containers, pipes and storage tanks. Preferably, the process comprises the additional step of regeneration of sulphuric acid from the fluidized tar/sludge.
Patent NZ-334241-A (NZ)
Title: Diagnosis of onset of bovine leukemia virus (BLV) and the resistance thereto
Inventor: AIDA YOKO
IPC: C12Q1/68
Filed: 1997-07-17
Abstract: The specification describes the diagnosis of onset of bovine leukemia caused by bovine leukemia virus (BLV).  The method involves the identification of an individual carrying the amino acid sequence Val-Asp-Thr-Tyr as specified by the amino acid numbers 75 to 78 in the 'beta'1 domain of the bovine MHC Class II DR'beta' chain.  Such an individual is judged to be predisposed to the onset of the disease. The resistance to the onset of bovine leukemia caused by BLV wherein an individual carrying the amino acid Val as the one specified by the amino acid number 78 in the 'beta'1 domain of the bovine MHC Class II DR'beta' chain may also be identified.
Patent NZ-334268-A (NZ)
Title: Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2]oct-3-yl) acetonitrile monohydrochloride
Inventor: MILOSOVICH SUSAN MARIE
IPC: A61P25/28
Filed: 1997-09-08
Abstract: The specification describes a controlled release oral dosage form containing [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2]oct-3-yl) acetonitrile monohydrochloride (compound X) and its use in the treatment and/or prophylaxis of dimentia.  The above compound is reported to enhance acetylcholine function via an an action at muscarinic receptors within the CNS
Patent NZ-335533-A (NZ)
Title: Shrink film having balanced properties or improved toughness
Inventor: PATEL RAJEN M
IPC: C08J5/18
Filed: 1997-11-13
Abstract: A shrink film obtained by selectively controlling and optimising the density differential between at least two polyolefin polymer components to provide narrow density splits. More specifically a biaxially oriented polyolefin shrink film having balanced properties and an oriented shrink film having improved toughness is provided. The shrink film is made by a biaxial orientation method of making using shrink orientation techniques such as tenter framing, double-bubble, trapped bubble, tape orientation or combinations thereof. Most preferably, the first polyolefin polymer component is a lower density, substantially linear ethylene/ alpha -olefin inter-polymer and the second polyolefin polymer component is a higher density, heterogeneously branched ethylene/ alpha -olefin inter-polymer.
Patent NZ-336533-A (NZ)
Title: Process to prepare tolterodine using the intermediate 3,4-Dihydro-6-methyl-4-phenyl-2H-benzopyran-2-ol
Inventor: GAGE JAMES R
IPC: C07D311/20
Filed: 1997-12-18
Abstract: A process for the production of tolterodine (V) compounds as seen in the above formula, including an intermediate, 3,4-dihydro-6-methyl-4-phenyl-2H-benzopyran-2-ol (IV).  The tolterodine (V) compound comprises R-tolterodine L-tartrate The process involves reducing a lactone with a reducing agent, preferably diisobutylaluminium hydride, sodium bis(2-methoxyethoxy)aluminium or lithium tri-tert-butyoxyaluminohydride, to form a hydroxy compound, then reductively aminating the hydroxy compound with diisopropylamine.  Reduction of the lactone occurs at less than -15oC.
Patent NZ-336834-A (NZ)
Title: Feeding bottle with inner chamber containing cooling medium
Inventor: TEGLBJARG CASPAR
IPC: A61J9/00
Filed: 1999-07-20
Abstract: A baby's feeding bottle 2 is constructed with a cylindrical compartment 12 extending upwards from the bottom of the bottle.  The compartment is closed at its upper end, and contains a cooling means.  This may be a container of a chilled liquid, such as water.  The bottle is surrounded by sleeve 3, which extends below the bottom of the bottle, so as to form a chamber for storage of a teat 11 or packet of milk powder 5. Addition to 336834
Patent NZ-501486-A (NZ)
Title: Forming optical fibre preform by deposition of vapour produced by combustionless hydrolysis
Inventor: ROBA GIACOMO STEFANO
IPC: B01J13/00
Filed: 1999-12-03
Abstract: A glass preform, for example, for optical fibres, is produced by depositing glass vapour onto a mandrel 26.  The glass vapour is produced by vaporizing a glass precursor 10 and water 12 and passing the heated vapours to a reaction chamber 14 where the glass vapour is produced by combustionless hydrolysis.  The glass vapour is then passed through a nozzle onto the mandrel 26.  A temperature gradient is maintained in the reaction chamber, such that the temperature increases from the inlet to the outlet.  The temperature difference may be such that the outlet is 100 - 300° hotter than the inlet.  The glass precursor and water may be provided to the reaction chamber at a temperature of 600 - 800°C.
Patent NZ-504086-A (NZ)
Title: Bis-quaternary ammonium derivatives of cyclic alkanol diesters useful as neuromuscular relaxants
Inventor: GYERMEK LASZLO
IPC: C07D451/14
Filed: 1998-09-24
Abstract: A bis-quaternary ammonium derivative of cyclic alkanol diester has the formula (I) wherein: R1 and R1' are di- or polysubstituted aralkyl or aralkenyl provided that at least one substituent on each aralkyl or aralkenyl group is alkoxy or acyloxy; R2 and R2' are alkyl or alkenyl; A is optionally substituted alkanedicarbonyl, alkenedicarbonyl, alkynedicarbonyl, cycloalkanedicarbonyl, cycloalkenedicarbonyl, bicycloalkanedicarbonyl, bicycloalkenedicarbonyl, polycycloalkanedicarbonyl, polycycloalkenedicarbonyl, or aromatic dicarbonyl; n is 0, 1, or 2; m is 0, 1, or 2 and p is 0, 1, or 2; R3 and R3' are H, CH3, or alkyl and R4 and R4' are H, CH3, or alkyl or together R3 and R4 can also be -(CH2)g -, -CH=CH-, -(CH2)h-O-(CH2)k-,a compound of formula (II)or  -(CH2)h-S-(CH2)k- or together R3' and R4' can also be -(CH2)g -, -CH=CH-, -(CH2)h-O-(CH2)k-,a compound of formula (II) or  -(CH2)h-S-(CH2)k-; g is 2, 3, 4, or 5; h is 1 or 2, and k is 1 or 2 and R1 and R1', R2 and R2', R3 and R3', and R4 and R4' can be the same or different; and X is a pharmaceutically acceptable anion. A pharmaceutical composition thereof is useful as a neuromuscular relaxant.
Patent NZ-506926-A (NZ)
Title: Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
Inventor: ESTELL DAVID A
IPC: C12N1/15
Filed: 1999-04-14
Abstract: A method of determining T-cell epitopes in humans whereby a solution of dendritic cells and a solution of naïve CD4+ and/or CD8+ T-cells from a single blood source, with differentiation promoted, is combined with a peptide of interest and the production of antibodies measured. Also disclosed is a method of reducing the allergenicity of a protein.
Patent NZ-507431-A (NZ)
Title: Process for the preparation of 3-pyridylsulphonyl substituted pyrazolo[4,3-d]pyrimidin-7-one derivatives and -1(2-pyridylmethyl)-1H-pyrazol-4-yl)-(5-1-piperazinylsulphonyl)-nicotinamide intermediates
Inventor: DEVRIES KEITH MICHAEL
IPC: C07D487/04
Filed: 2000-10-10
Abstract: A process preparing a compound formula (I) comprises reacting a compound of formula (II), (III) or (IV) in the presence of -OR and a hydroxide-trapping agent or in the case of compounds of formula (IV) reacting in the presence of an auxiliary base and a hydroxide-trapping agent wherein: X is a leaving group; R is optionally substituted alkyl; cycloalkyl; 1-alkyl piperidinyl; tetrahydrofuranyl or tetrahydropyranyl; R1 (which can be linked to either nitrogen of the pyrazole ring) is optionally substituted alkyl; R2 is alkyl; R3 and R4, together with the nitrogen atom to which they are attached, form an optionally substituted 4-R8-piperazinyl group optionally in the form of its 4-N-oxide and R8 is H; optionally substituted alkyl, alkenyl; pyridinyl or pyrimidinyl. Compounds of formulae (IVA) and (IVB) are described.
Patent NZ-511276-A (NZ)
Title: Synthesis of n-silylated cyclopentaphenanthrene compounds
Inventor: ASKHAM FREDRIC R
IPC: C07C13/68
Filed: 2000-08-31
Abstract: 1,3-dehydro-cyclopenta(1)phenanthren-2-one is reacted with an alkali metal borohydride such as sodium borohydride in tetrahydrofuran to produce 2,3-dihydro-1H-cyclopenta(1)phenanthren-2-ol. 2,3-dihydro-cyclopenta(1)phenanthren-2-ol is reacted with sulphonyl chloride and an anhydrous trialkylamine in a non-interfering solvent to produce methansulphonic acid 2,3-dihydro-cyclopenta(1)phenanthren-2-yl ester which is treated with potassium t-butoxide in  non-interfering solvent  to produce 1H-cyclopenta(1)phenanthren.
Patent NZ-513770-A (NZ)
Title: Adjustable antenna feed network with integrated phase shifter
Inventor: SLEDKOV VICTOR ALEKSANDROVICH
IPC: H01P5/04
Filed: 2001-08-24
Abstract: A device for feeding signals between a common line (10) and two or more ports (20-28), by including a branched network of feedlines (1-18) that couple the common line with the ports. A dielectric member (47a, 47b) is mounted adjacent to the network and can be moved to synchronously adjust the phase relationship between the common line and one or more of the ports. The feedlines and the dielectric member have transformer portions (11, 12, 29)&(91, 93) of varying widths for reducing reflection of signals passing through the network.
Patent NZ-520213-A (NZ)
Title: Substituted benzoylguanidines, method for their production, their use as a medicament or diagnostic agent and a medicament containing the same
Inventor: WEICHERT ANDREAS
IPC: A61P11/00
Filed: 2001-01-08
Abstract: The application describes a benzoylguanidine of the formula I (see below) wherein R2 stands for -Y-para-(C6H4)-R11, -Y-meta-(C6-H4)-R11 or -Y-ortho-(C6H4)-R11; R11 represents (C1-C9)-heteroaryl, which is bonded by C or N and is substituted or unsubstituted with 1 to 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxy, amino, methylamino, dimethylamino and benzyl; Y represents oxygen, -S- or NR12; R12 represents H or (C1-C4)-alkyl; R4 F, Cl, Br, I or C1-C4-alkyl; R1 and R3 are defined as per the claims. Said benzoylguanidines are suitable for use as anti-arrhythmic medicaments containing cardio protective components for the prophylaxis and treatment of infarcts and for the treatment of angina pectoris. They also preventively inhibit the patho-physiological processes associated with the origination of defects caused by ischemia, in particular during the triggering of ischemically induced cardiac arrhythmia.
Patent NZ-520258-A (NZ)
Title: Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
Inventor: DESCHENES DENIS
IPC: C07D417/10
Filed: 2000-12-20
Abstract: Described are substituted 8-arylquinoline compounds of formula (I), for which the substituents are defined herein. The compounds are used in the manufacture of medicaments for the treatment of diseases mediated by the inhibition of phosphodiesterase-4 (PDE4).